Codexis (CDXS) Stock: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$1.37
0.01 (0.74%)
▲
5d:
+3.79%
30d:
-7.12%
90d:
-48.5%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CDXS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CDXS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $1.37, which is considered oversold relative to its 30-day fair value range of $1.35 to $1.60. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.2) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong downtrend. Immediate support is located at $1.31, while resistance sits at $1.43.
Market Sentiment: CDXS scores 81/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.14 (+351.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CDXS is in a strong downtrend. Immediate support is located at $1.31, while resistance sits at $1.43.
Market Sentiment: CDXS scores 81/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $6.14 (+351.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.35 -
$1.60
Company Quality Score
72/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (81/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 351.7% below Wall St target ($6.14)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 20% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.35 -
$1.60
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.31
Resistance Level
$1.43
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.25
Wall Street Target
$6.14
(+351.7%)
Revenue Growth (YoY)
-2.7%
Profit Margin
-39.6%
PE vs Historical
-4.3 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: October 02, 2026 11:33 AM ET
Data refreshes hourly during market hours. Next update: 12:33 PM
Data refreshes hourly during market hours. Next update: 12:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 68 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 68 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 48 HOLD |
